Every year the peptide hype cycle produces compounds that go from "interesting preclinical data" to "life-changing protocol" in roughly the time it takes an Instagram account to find affiliate links. These five are the most egregious examples heading into 2026 — not because the compounds are entirely without interest, but because the gap between the claims and the evidence is particularly large.

1. Dihexa — "The Most Powerful Nootropic Ever Discovered"

The claim: Dihexa is 100,000 times more potent than BDNF (brain-derived neurotrophic factor) and represents a breakthrough in cognitive enhancement.

The evidence: The "100,000x" figure comes from a single 2013 cell culture assay measuring synaptogenic potency — not cognitive enhancement in animals, not human cognition, not clinical outcomes. It's a measure of how much compound was needed to produce a certain effect in isolated cells. The same research group that published this result also noted, in a separate paper, that Dihexa promotes tumor growth in models with pre-existing cancer. Zero human trials have been conducted. The compound has generated negligible follow-up research from independent groups in the decade since the original paper.

Why it's still being hyped: "100,000x more potent than BDNF" is an extraordinary marketing sentence. It sounds like the kind of thing that ends careers in pharmacology if it's not true. The fact that it comes from a cell culture study rather than anything relevant to human cognition gets dropped in the retelling, every time.

Risk note: Dihexa's potential tumor-promoting activity is not a theoretical concern — it was observed in the same research that generated the potency claims. This is not a compound with a benign unknown profile. It has a specific known concerning signal that should elevate caution substantially above baseline.

2. Follistatin 344 — "Superhuman Muscle Without the Work"

The claim: Follistatin 344 builds superhuman muscle mass by blocking myostatin, the natural inhibitor of muscle growth. Some protocols promise results that exceed what's achievable with anabolic steroids.

The evidence: Follistatin's mechanism is real — it does inhibit myostatin and activin, both of which negatively regulate skeletal muscle mass. Cattle bred with myostatin mutations develop dramatically increased musculature. Children with natural myostatin deficiency are documented to have extraordinary muscle development. The gene therapy data in animals is genuinely striking.

The problem is that "follistatin peptide injections" are not "follistatin gene therapy." The protein is large and has poor subcutaneous bioavailability. Systemic myostatin inhibition has documented effects on cardiac muscle that are concerning at high doses. The one human gene therapy trial (for Duchenne muscular dystrophy) showed modest, not superhuman, results. Gray-market "Follistatin 344" peptide products have not been validated for purity or correct synthesis in any independent assay.

Why it's still being hyped: The mechanism is compelling and the animal results are visually dramatic. Bodybuilding communities have an established history of adopting compounds with compelling mechanisms before clinical evidence exists (see: IGF-1, MGF, various SARMs). The pattern repeats because the incentives favor confident early adoption over cautious waiting.

3. Epithalon — "Anti-Aging Through Telomere Extension"

The claim: Epithalon lengthens telomeres and thereby reverses aging, reducing biological age and extending healthy lifespan.

The evidence: Epithalon (a synthetic tetrapeptide: Ala-Glu-Asp-Gly) does appear to activate telomerase in vitro and in some animal studies, primarily from one Russian research group (Khavinson et al.) over a period of decades. The challenge: telomere length is correlated with aging but causality in the other direction — whether lengthening telomeres produces lifespan extension in otherwise normal mammals — is not established. Critically, unconstrained telomerase activation is also a hallmark of cancer. The independent replication of Khavinson's results is thin. No rigorous human trials exist.

Why it's still being hyped: The anti-aging industry has enormous demand for compounds that claim to reverse aging biomarkers. Telomere length is a well-known aging biomarker, making "telomere extension" a compelling pitch even if the relationship between telomere length intervention and actual aging outcomes is far from clear. The Russian research literature has historically been harder for Western researchers to access and critique, which can create an appearance of stronger evidence than the data supports.

4. AOD-9604 — "Fat Loss Without Diet or Exercise"

The claim: AOD-9604 burns fat without diet or exercise through targeted lipolysis, delivering weight loss results that don't require behavioral change.

The evidence: AOD-9604 is a fragment of human growth hormone (residues 176-191) that was specifically developed by Monash University and licensed to Metabolic Pharmaceuticals as an anti-obesity drug. It went through Phase I, Phase II, and Phase III trials — a rarity among peptides currently marketed to consumers. The Phase III trial for obesity failed to demonstrate statistically significant weight loss compared to placebo. The compound achieved GRAS (Generally Recognized as Safe) status from the FDA in 2014 as a food additive, which the supplement industry has since misrepresented as evidence of efficacy.

Why it's still being hyped: Technically, AOD-9604 did have human trials, which the marketing uses as evidence of legitimacy. What the marketing reliably omits is that the Phase III trial failed and the drug was never approved for any indication. "FDA GRAS" sounds like an endorsement of efficacy. It's an endorsement of safety at the doses used in food additives — a completely different standard.

5. DSIP — "The Sleep Architecture Reset"

The claim: DSIP (Delta Sleep-Inducing Peptide) fixes insomnia and resets disrupted sleep architecture, including normalizing slow-wave sleep in people with chronic sleep disorders.

The evidence: DSIP was identified in 1977 in rabbit cerebrospinal fluid and generated significant research interest through the 1980s and early 1990s. Several small human studies (typically n < 20) showed some effects on sleep architecture, particularly in certain populations. Then the research largely stopped. Why? Results were inconsistent across studies, the pharmacokinetics were difficult to characterize, and the compound's mechanism of action was never clearly established. The 1990s produced a different class of sleep compounds (hypnotics, then later orexin antagonists) that were more tractable.

The revival of DSIP in biohacking circles is largely driven by a few small older studies rather than current research. The evidence that remains is not strong by modern standards: small samples, inconsistent outcomes, no placebo-controlled trials with adequate power, and no established dosing for any specific sleep indication.

Why it's still being hyped: Sleep is a massive pain point. Any compound that was ever studied for sleep effects and cleared basic safety thresholds will find a market. The old literature is genuine — it just doesn't support the confident claims being made in 2026 based on it.

The Common Thread

Every compound on this list has a real mechanism and real research behind it. None of them have the human efficacy data that would justify the specific claims being made about them. The pattern: plausible mechanism + limited positive animal data + zero or failed human trials + enthusiastic marketing = overhyped peptide.

The answer isn't to dismiss everything. It's to match your confidence to your evidence. If you want to know where a specific claim actually sits, score it. The BS score isn't an opinion — it's a calibrated read against the published research. That's the difference between making an informed decision and buying a story.